NASDAQ:ONTXOnconova Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Onconova Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.29 0.00 (0.00 %) (As of 04/9/2020 08:14 AM ET) Add Compare Share Today's Range$0.28Now: $0.29▼$0.3050-Day Range$0.28MA: $0.38▼$0.5452-Week Range$0.10Now: $0.29▼$4.45Volume2.82 million shsAverage Volume6.94 million shsMarket Capitalization$49.19 millionP/E RatioN/ADividend YieldN/ABeta2.22 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingOnconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.43, Onconova Therapeutics has a potential upside of 3,787.6% from its current price of $0.29.Amount of Analyst CoverageOnconova Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesOnconova Therapeutics has received 336 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOnconova Therapeutics has received 288 “underperform” votes. (Add your “underperform” vote.)Community SentimentOnconova Therapeutics has received 53.85% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote “Outperform” if you believe ONTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOnconova Therapeutics does not currently pay a dividend.Dividend GrowthOnconova Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Onconova Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.70% of the stock of Onconova Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.10% of the stock of Onconova Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Onconova Therapeutics are expected to grow by 27.27% in the coming year, from ($0.11) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Onconova Therapeutics is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Onconova Therapeutics is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOnconova Therapeutics has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONTX Previous Symbol CUSIPN/A CIK1130598 Webhttp://www.onconova.com/ Phone267-759-3680Debt Debt-to-Equity RatioN/A Current Ratio2.83 Quick Ratio2.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.18 million Price / Sales22.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book3.68Profitability EPS (Most Recent Fiscal Year)($1.49) Net Income$-21,500,000.00 Net Margins-985.02% Return on EquityN/A Return on Assets-173.41%Miscellaneous Employees25 Outstanding Shares167,260,000Market Cap$49.19 million Next Earnings Date5/12/2020 (Estimated) OptionableNot Optionable Receive ONTX News and Ratings via Email Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ONTX Rates by TradingView Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions How has Onconova Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Onconova Therapeutics' stock was trading at $0.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ONTX shares have decreased by 18.3% and is now trading at $0.2941. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Onconova Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Onconova Therapeutics. When is Onconova Therapeutics' next earnings date? Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Onconova Therapeutics. How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics Inc (NASDAQ:ONTX) announced its earnings results on Tuesday, August, 14th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.15. The biopharmaceutical company earned $0.49 million during the quarter, compared to analysts' expectations of $0.52 million. View Onconova Therapeutics' earnings history. When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work? Onconova Therapeutics's stock reverse split on the morning of Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split. What price target have analysts set for ONTX? 3 brokers have issued 12-month target prices for Onconova Therapeutics' shares. Their forecasts range from $1.30 to $25.00. On average, they anticipate Onconova Therapeutics' stock price to reach $11.43 in the next year. This suggests a possible upside of 3,787.6% from the stock's current price. View analysts' price targets for Onconova Therapeutics. Has Onconova Therapeutics been receiving favorable news coverage? News coverage about ONTX stock has been trending very negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Onconova Therapeutics earned a news impact score of -3.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutOnconova Therapeutics. Who are some of Onconova Therapeutics' key competitors? Some companies that are related to Onconova Therapeutics include Abeona Therapeutics (ABEO), XOMA (XOMA), Lexicon Pharmaceuticals (LXRX), OptiNose (OPTN), NuCana (NCNA), Recro Pharma (REPH), Protagonist Therapeutics (PTGX), Mallinckrodt (MNK), Hookipa Pharma (HOOK), Scpharmaceuticals (SCPH), Paratek Pharmaceuticals (PRTK), VBI Vaccines (VBIV), IVERIC bio (ISEE), MEI Pharma (MEIP) and Selecta Biosciences (SELB). What other stocks do shareholders of Onconova Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Opko Health (OPK), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), FuelCell Energy (FCEL), Agile Therapeutics (AGRX) and Novavax (NVAX). Who are Onconova Therapeutics' key executives? Onconova Therapeutics' management team includes the following people: Dr. Steven M. Fruchtman, CEO, Pres & Director (Age 68)Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 75)Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 56)Dr. Ramesh Kumar, Advisor (Age 63)Mr. Mark Patrick Guerin, Chief Financial Officer (Age 50) What is Onconova Therapeutics' stock symbol? Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX." How do I buy shares of Onconova Therapeutics? Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Onconova Therapeutics' stock price today? One share of ONTX stock can currently be purchased for approximately $0.29. How big of a company is Onconova Therapeutics? Onconova Therapeutics has a market capitalization of $49.19 million and generates $2.18 million in revenue each year. The biopharmaceutical company earns $-21,500,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe. View additional information about Onconova Therapeutics. What is Onconova Therapeutics' official website? The official website for Onconova Therapeutics is http://www.onconova.com/. How can I contact Onconova Therapeutics? Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: Which market index is the best?
